Financhill
Back

Intellia Therapeutics Quote, Financials, Valuation and Earnings

Get Free, Instant Access To Today's Top Stocks List!

View this list for FREE now!
Sell
31

NTLA
Intellia Therapeutics

Last Price:
38.29
Seasonality Move:
10.02%

7 Day Trial

ALL ACCESS PASS

$ 7

10 POWERFUL Patterns...

Click here to download your copy now

Intellia Therapeutics Price Quote

$38.29
-0.01 (2.99%)
(Updated: March 25, 2023 at 5:22 AM ET)

Intellia Therapeutics Key Stats

Sell
31
Intellia Therapeutics (NTLA) is a Sell

Day range:
$36.46 - $38.40
52-week range:
$32.44 - $78.58
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
56.56
P/B ratio:
2.73%

Volume:
764.7K
Avg. volume:
1.2M
1-year change:
-46.81%
Market cap:
$3.4B
Revenue:
$52.1M
EPS:
$-6.18

How Much Does Intellia Therapeutics Make?

Is Intellia Therapeutics Growing As A Company?

  • What Is Intellia Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.06%
  • What Is Intellia Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Intellia Therapeutics Stock Price Performance

What Is Intellia Therapeutics 52-Week High & Low?

Intellia Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Intellia Therapeutics?

Is Intellia Therapeutics Cash Flow Positive?

  • What Is NTLA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$333.3M
  • What Is Intellia Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $583M
  • What Is Intellia Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $160.3M

Intellia Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    NTLA return on invested capital is -48.04%
  • What Is Intellia Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -38.17%
  • What Is NTLA Return On Equity?
    ROE is a measure of profitability and is -48.04%

Intellia Therapeutics Earnings Date & Stock Price

Intellia Therapeutics Competitors

Intellia Therapeutics Dividend Yield

Data Unavailable

Intellia Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -0.41%
Revenue: 5.59% 26.72%

Analyst Recommendations

Buy Recommendations: 17
Hold Recommendations: 4
Sell Recommendations: 0
Price Target: 94.41
Upside from Last Price: 146.49%

Major Shareholders

  • How many NTLA shares are owned by institutional investors?
    114.6M NTLA shares are owned by institutional investors
  • How many NTLA shares are owned by insiders?
    2.2M NTLA shares are owned by insiders